◀ Back to PARP14
BCL6 — PARP14
Pathways - manually collected, often from reviews:
-
NCI Pathway Database IL4-mediated signaling events:
IRF4/BCL6 complex (IRF4-BCL6)
→
STAT6 (dimer)/PARP14 complex (STAT6-PARP14)
(transcription, inhibits)
Gupta et al., J Exp Med 1999, Schroder et al., J Immunol 2002, Goenka et al., Proc Natl Acad Sci U S A 2006, Kotanides et al., Science 1993, Takeda et al., Nature 1996, Ryan et al., Immunity 1996
Evidence: mutant phenotype, reporter gene, physical interaction, other species
Text-mined interactions from Literome
Jang et al., Biochem Biophys Res Commun 2002
:
The L-canavanine induced caspase-3 activation, degradation of
PARP , and apoptotic DNA fragmentation were
suppressed by ectopic expression of Bcl-2 or
Bcl-xL , both of which are known to play roles as anti-apoptotic regulators
Kawano et al., Anticancer Res 2004
(MAP Kinase Signaling System) :
The combination treatment activated caspase-3 and cleaved
PARP , but it did not
induce any notable change in the expression of
Bcl-XL , Bcl-2 and Bax compared with each single treatment
Ibrado et al., Cancer Res 1996
:
In the present studies, we determined the
effect of high intracellular levels of the antiapoptosis Bcl-2 or
Bcl-xL protein on Yama protease activation and
PARP degradation during Ara-C induced apoptosis ... High Bcl-2 and
Bcl-xL levels in these cells also
inhibited Yama protease activity,
PARP degradation, and apoptosis due to clinically relevant concentrations of etoposide and mitoxantrone